Cancer cells may evade the immune response thanks to a special type of collagen, scientists reported in a new study published in the July 21, 2022, issue of Cancer Cell. Researchers at The University of Texas MD Anderson Cancer Center have discovered oncogenic collagen secreted by cancer cells that differs from normal collagen.

As part of its drug competition action plan, the U.S. FDA issued a draft guidance on the evaluation of therapeutic equivalence.